Results: In the present research, the total mortality ratio in the unvaccinated patient group was 8.2%, while the overall mortality rate in the patient group vaccinated was 0% (p = .043).
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Purpose: The purpose of our research is to determine the protective impact of CoronaVac vaccine in individuals under the age of 40 and over the age of 18 who have had COVID-19 infection.
📊
Key Findings & Data:Material and Methods: Patients aged 18-40 years who applied to our hospital with COVID-19 + as a test were divided into two groups according to their coronaVac vaccine status, and the morbidity and mortality of the patients were investigated.
💡
Conclusion & Impact:Results: In the present research, the total mortality ratio in the unvaccinated patient group was 8.2%, while the overall mortality rate in the patient group vaccinated was 0% (p = .043).
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:CoronaVac · age · vaccine.
Abstract
Purpose: The purpose of our research is to determine the protective impact of CoronaVac vaccine in individuals under the age of 40 and over the age of 18 who have had COVID-19 infection. Material and Methods: Patients aged 18-40 years who applied to our hospital with COVID-19 + as a test were divided into two groups according to their coronaVac vaccine status, and the morbidity and mortality of the patients were investigated. Results: In the present research, the total mortality ratio in the unvaccinated patient group was 8.2%, while the overall mortality rate in the patient group vaccinated was 0% (p = .043). Conclusion: The 0% mortality rate in persons who received two doses of CoronaVac vaccine clearly shows the effect of the vaccine on mortality.
KOCA, E., KUTLUSOY, S., AYDIN, A., KASAPOĞLU, U. S. (2023). The influence of SARS-CoV-2 vaccination on 28-day mortality and hospitalization rate of COVID-19 patients under 40 years. Türk Fen ve Sağlık Dergisi, Cilt: 4 Sayı: 2, 147–154. https://ajindex.com/articles/938110
Amato, M. K., Hennessy, C., Shah, K., Mayer, J. (2021).Multisystem Inflammatory Syndrome in an Adult. The Journal of emergency medicine, 61(1), 1–3. https://doi.org/10.1016/j.jemermed.2021.02.007
Chaimayo, C., Kaewnaphan, B., Tanlieng, N., Athipanyasilp, N., Sirijatuphat, R., Chayakulkeeree, M., Angkasekwinai, N., Sutthent, R., Puangpunngam, N.,Tharmviboonsri, T., Pongraweewan, O., Chuthapisith, S., Sirivatanauksorn, Y., Kantakamalakul, W.,Horthongkham, N. (2020). Rapid SARS-CoV-2 antigen detection assay in comparison with real-time RT-PCRassay for laboratory diagnosis of COVID-19 in Thailand. Virology journal, 17(1), 177. https://doi.org/10.1186/s12985-020-01452-5
Chen LK. (2021). COVID‐19 vaccination and frailty in older adults. Arch Gerontol Geriatr, 96:104487. https://doi: 10.1016/j.archger.2021.104487 Cömert, SŞ., Kıral, N. (2020). Radiological Findings ofCOVID-19 Pneumonia. Southern Clinics of Istanbul Eurasia, 31: 16-22.https://doi.org/10.14744/scie.2020.96158
Diken ÖE. (2021).
SARS-CoV, MERS-CoV Neler Öğrendik? SARS-CoV2 ile Farklılıkları. ASYOD Güncel Göğüs Hastalıkları Serisi Kitapları. In: Karadağ M. Ankara: Dünya Tıp Kitapevi. 35-43.
Eastin, C., Eastin, T. (2020). Clinical Characteristics of Coronavirus Disease 2019 in China: Guan W, Ni Z, Hu Y, et al. N Engl J Med. 2020 Feb 28 [Online ahead of print] DOI: 10.1056/NEJMoa2002032. The Journal of Emergency Medicine, 58(4), 711–712. https://doi.org/10.1016/j.jemermed.2020.04.004
Fang, X., Li, S., Yu, H., Wang, P., Zhang, Y., Chen, Z., Li, Y., Cheng, L., Li, W., Jia, H., Ma, X. (2020). Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and metaanalysis. Aging, 12(13), 12493–12503. https://doi.org/10.18632/aging.103579
Ganesan, R., Mahajan, V., Singla, K., Konar, S., Samra, T., Sundaram, S. K., Suri, V., Garg, M., Kalra, N., Puri, G. D.(2021). Mortality Prediction of COVID-19 Patients at Intensive Care Unit Admission. Cureus, 13(11), 19690. https://doi.org/10.7759/cureus.19690
Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y.,Zhu, L., Wang, N., Lv, Z., Gao, H., Ge, X., Kan, B., Hu, Y., Liu, J., Cai, F., Jiang, D., Yin, Y., Qin, C., Li, J., … Qin, C.(2020). Development of an inactivated vaccinecandidate for SARS-CoV-2. Science (New York,N.Y.), 369(6499), 77–81. https://doi.org/10.1126/science.abc1932
Hani, C., Trieu, N. H., Saab, I., Dangeard, S., Bennani, S.,Chassagnon, G., Revel, M. P. (2020). COVID-19 pneumonia: A review of typical CT findi